Table 2

 Change in WOMAC subscales* from baseline to week 6 and effect size for knee and hip for the naproxen and placebo treated groups

WOMAC subscalePainStiffnessPhysical function
*Values are mean (SD).
BL, baseline; CI, confidence interval; WOMAC, Western Ontario and McMaster Universities osteoarthritis index.
Knee (naproxen)(n = 280)(n = 279)(n = 278)
    BL44.2 (20.5)48.9 (24.1)47.1 (21.0)
    BL-6−16.62 (20.50)−19.39 (23.01)−16.31 (17.89)
    Effect size0.810.800.78
Knee (placebo)(n = 75)(n = 75)(n = 72)
    BL45.11 (20.3)50.6 (25.9)48.2 (19.8)
    BL-6−6.75 (19.12)−9.33 (23.91)−6.75 (18.05)
    Effect size0.330.360.34
Hip (naproxen)(n = 123)(n = 123)(n = 123)
    BL47.3 (22.2)49.3 (23.7)49.7 (22.9)
    BL-6−12.33 (19.78)−12.97 (21.52)−11.66 (16.78)
    Effect size0.560.550.51
Hip (placebo)(n = 33)(n = 33)(n = 33)
    BL44.7 (20.1)48.6 (23.3)47.5 (21.8)
    BL-6−3.24 (22.27)−8.15 (20.88)−4.35 (17.67)
    Effect size0.160.350.20
Difference response knee–hip (95% CI), naproxen−4.66 (−8.83 to −0.50), p = 0.03−6.64 (−11.16 to −2.11), p = 0.004−4.77 (−9.82 to −0.90), p = 0.016
Difference response knee–hip (95% CI), placebo−2.89 (−11.37 to 5.59), p = 0.50−0.10 (−9.25 to 9.05), p = 0.98−2.29 (−9.82 to 5.24), p = 0.55